Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
RVTY gained 13.3% after Q2 adjusted EPS of $1.41 beat the $1.23 consensus on $730 million of revenue, prompting higher full-year revenue and profit guidance. Diagnostics, AI-enabled drug discovery and the SuperFlex launch add product momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Cash Flow ⢠Weak Profitability ⢠High Intangibles RVTY has strong liquidity and cash flow, but weak profitability, high intangible-asset exposure, and elevated valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Strong monthly gain ⢠Near resistance ⢠Pullback risk Support Level: $140.00; stronger support $130.00â$131.00 Resistance Level: $147.00 RVTY gained 16% over the last month and remains bullish above $140, but near-$147 resistance and elevated momentum favor waiting for a confirmed breakout or pullback.
Sentiment & News
Key News Insights: ⢠Raised 2026 outlook ⢠Strategic cell acquisition ⢠Valuation risks persist Revvity's upgraded outlook, strong stock momentum, and planned Human Cell Design acquisition support a constructive long-term view, though elevated valuation and estimate-revision risks warrant caution.
AI Summary
Revvity's improving Diagnostics growth, cash conversion, and software/AI strategy support a credible recovery, but at roughly 60x earnings after a major rally, investors should wait for broader life-sciences acceleration and sustained margin expansion before underwriting the premium valuation.
Description
Revvity, Inc. supplies instruments, reagents, software and laboratory services across diagnostics, life sciences research and applied markets globally through two reporting segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions unit sells research tools, informatics, imaging and analytical technologies used in academic and industrial research, environmental testing, food and agricultural applications, and industrial process monitoring, while the Diagnostics segment provides assay platforms, tests and supporting software for genetic and infectious disease screening and for genomic workflows in oncology and drug discovery. The company serves pharmaceutical and biotech firms, clinical and public health laboratories, academic institutions, healthcare providers and government agencies; it was founded in 1937, is headquartered in Waltham, Massachusetts, and changed its name from PerkinElmer in April 2023.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 1 | Sep 8 | RVTY | Revvity, Inc. | RVTY gained 13.3% after Q2 adjusted EPS of $1.41 beat the $1.23 consensus on $730 million of revenue, prompting higher full-year revenue and profit guidance. Diagnostics, AI-enabled drug discovery and the SuperFlex launch add product momentum. | Closed | +0.4% |